Latest Insider Transactions at Bei Gene, Ltd. (BGNE)
This section provides a real-time view of insider transactions for Bei Gene, Ltd. (BGNE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BeiGene, Ltd. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BeiGene, Ltd.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 14
2025
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Mar 11
2025
|
Xiaodong Wang Director |
SELL
Bona fide gift
|
Direct |
158,717
-3.03%
|
-
|
|
Mar 10
2025
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
41,210
-39.18%
|
$9,972,820
$242.91 P/Share
|
|
Mar 10
2025
|
John Oyler Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
41,210
+50.0%
|
$247,260
$6.5 P/Share
|
|
Mar 10
2025
|
John Oyler Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
497,822
+7.55%
|
$0
$0.5 P/Share
|
|
Mar 07
2025
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
58,590
-32.93%
|
$14,647,500
$250.34 P/Share
|
|
Mar 07
2025
|
John Oyler Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
58,590
+50.0%
|
$351,540
$6.5 P/Share
|
|
Mar 07
2025
|
John Oyler Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
708,747
+11.23%
|
$0
$0.5 P/Share
|
|
Mar 06
2025
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,109
-52.81%
|
$10,428,340
$260.48 P/Share
|
|
Mar 06
2025
|
John Oyler Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,109
+50.0%
|
$240,654
$6.5 P/Share
|
|
Mar 06
2025
|
John Oyler Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
486,161
+9.04%
|
$0
$0.5 P/Share
|
|
Mar 05
2025
|
John Oyler Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
201,084
+4.36%
|
-
|
|
Mar 05
2025
|
Aaron Rosenberg Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
48,581
+22.52%
|
-
|
|
Mar 05
2025
|
Chan Henry Lee SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
40,209
+14.04%
|
-
|
|
Mar 05
2025
|
Lai Wang Global Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
69,251
+6.54%
|
-
|
|
Mar 05
2025
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
51,921
-66.69%
|
$13,551,381
$261.88 P/Share
|
|
Mar 05
2025
|
Xiaobin Wu President, COO & GM China |
BUY
Exercise of conversion of derivative security
|
Direct |
51,921
+48.18%
|
$7,476,624
$144.8 P/Share
|
|
Mar 05
2025
|
Xiaobin Wu President, COO & GM China |
BUY
Grant, award, or other acquisition
|
Direct |
103,883
+8.12%
|
-
|
|
Mar 04
2025
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Indirect |
8,146
-42.76%
|
$2,069,084
$254.67 P/Share
|
|
Mar 03
2025
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
101,000
-35.47%
|
$24,644,000
$244.98 P/Share
|
|
Mar 03
2025
|
John Oyler Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
101,000
+50.0%
|
$606,000
$6.5 P/Share
|
|
Mar 03
2025
|
John Oyler Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,220,531
+22.52%
|
$0
$0.5 P/Share
|
|
Feb 28
2025
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Feb 28
2025
|
Baker Bros. Advisors LP |
SELL
Open market or private sale
|
Indirect |
732,827
-7.69%
|
$190,535,020
$260.0 P/Share
|
|
Feb 27
2025
|
Chan Henry Lee SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
1,205
-100.0%
|
$331,375
$275.0 P/Share
|
|
Feb 21
2025
|
Chan Henry Lee SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
1,202
-75.87%
|
$310,116
$258.58 P/Share
|
|
Feb 21
2025
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Indirect |
5,000
-42.67%
|
$1,285,000
$257.41 P/Share
|
|
Feb 20
2025
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
21,267
-100.0%
|
$5,104,080
$240.07 P/Share
|
|
Feb 20
2025
|
Xiaobin Wu President, COO & GM China |
BUY
Exercise of conversion of derivative security
|
Direct |
21,267
+50.0%
|
$3,594,123
$169.65 P/Share
|
|
Feb 18
2025
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
30,654
-78.45%
|
$7,387,614
$241.22 P/Share
|
|
Feb 18
2025
|
Xiaobin Wu President, COO & GM China |
BUY
Exercise of conversion of derivative security
|
Direct |
30,654
+50.0%
|
$5,180,526
$169.65 P/Share
|
|
Feb 04
2025
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Direct |
41,760
-47.05%
|
$9,396,000
$225.64 P/Share
|
|
Feb 04
2025
|
Xiaodong Wang Director |
BUY
Exercise of conversion of derivative security
|
Direct |
41,760
+50.0%
|
$250,560
$6.5 P/Share
|
|
Jan 07
2025
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Direct |
41,760
-63.13%
|
$7,391,520
$177.42 P/Share
|
|
Jan 07
2025
|
Xiaodong Wang Director |
BUY
Exercise of conversion of derivative security
|
Direct |
41,760
+50.0%
|
$250,560
$6.5 P/Share
|
|
Dec 14
2024
|
John Oyler Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,300,000
+30.38%
|
$0
$0.5 P/Share
|
|
Dec 10
2024
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Direct |
41,760
-41.7%
|
$7,892,640
$189.29 P/Share
|
|
Dec 10
2024
|
Xiaodong Wang Director |
BUY
Exercise of conversion of derivative security
|
Direct |
41,760
+50.0%
|
$250,560
$6.5 P/Share
|
|
Dec 09
2024
|
Baker Bros. Advisors LP |
SELL
Open market or private sale
|
Indirect |
1,037,017
-4.92%
|
$204,292,349
$197.25 P/Share
|
|
Dec 06
2024
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Dec 02
2024
|
Hhlr Advisors, Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
17,842,500
-12.49%
|
$3,568,500,000
$200.0 P/Share
|
|
Nov 26
2024
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Indirect |
7,883
-40.87%
|
$1,489,887
$189.62 P/Share
|
|
Nov 26
2024
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Direct |
40,468
-21.29%
|
$7,648,452
$189.69 P/Share
|
|
Nov 26
2024
|
Xiaodong Wang Director |
BUY
Exercise of conversion of derivative security
|
Direct |
38,461
+48.73%
|
$230,766
$6.5 P/Share
|
|
Oct 08
2024
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
10,000
-35.4%
|
$2,320,000
$232.77 P/Share
|
|
Oct 08
2024
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,175
-35.41%
|
$1,432,600
$232.77 P/Share
|
|
Sep 30
2024
|
Shalini Sharp Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,151
+50.0%
|
-
|
|
Sep 30
2024
|
Chan Henry Lee SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
1,202
-100.0%
|
$284,874
$237.1 P/Share
|
|
Sep 27
2024
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Indirect |
5,000
-100.0%
|
$1,100,000
$220.35 P/Share
|
|
Sep 19
2024
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
4,500
-100.0%
|
$900,000
$200.14 P/Share
|